Merck & Company Inc
I · Análisis con IA
En breve
Merck develops and sells prescription medicines for cancer, vaccines for diseases like HPV and rotavirus, and treatments for diabetes, HIV, and infectious diseases under brands like Keytruda, Gardasil, Januvia, and Bridion [Company Overview]. The company also operates a substantial animal health business selling livestock vaccines, companion animal treatments like Bravecto flea medication, and livestock intelligence solutions through its Allflex brand [Company Overview]. Merck partners with other pharma companies including Daiichi Sankyo, AstraZeneca, and Moderna to co-develop experimental treatments across multiple disease areas [Company Overview].
Merck is a major pharmaceutical company that develops and sells prescription drugs, vaccines, and animal health products worldwide [Yahoo Finance]. Its blockbuster cancer drug Keytruda is a cornerstone revenue driver, and the company recently announced breakthrough Phase 3 trial results for a new cancer treatment targeting endometrial cancer [Yahoo Finance]. With a market cap of $282.2 billion and strong margins, Merck operates as one of the largest drugmakers globally, though it faces typical pharmaceutical risks including patent cliffs and regulatory hurdles [Yahoo Finance].
Merck demonstrates strong profitability and a solid balance sheet with high margins and manageable debt levels [Yahoo Finance].
Puntuación Sentinellis
8.4/10
Financially healthy
Capitalización bursátil
$282.2B
Ingresos (12 meses)
$64.9B
II · Noticias recientes
Qué movió el precio
6 stories · ranked by relevance
- macro2026-05-20
How Investors Are Reacting To Merck (MRK) TroFuse ADC’s Breakthrough Endometrial Cancer Phase 3 Trial Results
Yahoo Finance
- macro2026-05-20
Merck and eschbach's PMWS Workshop Accelerates Pharma Execution via the "Intelligent Visual Factory"
Yahoo Finance
- macro2026-05-19
Merck’s Sacituzumab Tirumotecan Data Reframes Outlook For Oncology And Valuation
Simply Wall St
- macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- macro2026-05-18
How The Merck (MRK) Investment Story Is Shifting With Terns Deal And Oncology Updates
Simply Wall St
- macro2026-05-18
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
Zacks
Premium · gratis con cualquier cuenta
Merck's revenue growth of only 1.2% year-over-year indicates the company is facing headwinds, likely from patent expirations on older drugs or competitive pressure in key therapeutic areas [Yahoo Finance].
Riesgos
5
Oportunidades
6
Señales de alerta
1
Dirección
10
21 hallazgos más en el informe completo — gratis con cualquier cuenta.
Desbloquea el análisis completo de Merck & Company Inc
Crea una cuenta gratuita para acceder al informe completo generado con IA, con fuentes citadas en el texto.
- 5 riesgos, 6 oportunidades y 1 señal de alerta — cada uno con su fuente
- Más de 100 métricas financieras con gráficos y comparativas
- Resúmenes completos de noticias con enlaces a las fuentes
- Equipo directivo y remuneración
- Exportación a PDF para leer sin conexión
III · Empresas similares
También te puede interesar
Same sector · Healthcare or comparable health
¿La añades a tu lista?